PRVCF
PreveCeutical Medical Inc.·Healthcare
0.02
0.000%(+0.00)
Close PriceLast Updated: — ET
52W L: $0.0052W H: $0.04
PreveCeutical Medical Inc.·Healthcare
Vancouver, British Columbia--(Newsfile Corp. - April 1, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCID: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") announces that it has elected to rely on Coordinated Blanket Order 51-933 and move to semi-annual financial reporting ("SAR"). Coordinated Blanket Order 51-93 allows eligible venture issuers listed on the Canadian Securities Exchange (the "CSE") to voluntarily move from a quarterly to a semi-annual financial reporting framework.
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce the appointment of Dr. Raj S. Pruthi, MD, MHA, FACS, to its Board of Directors.
Vancouver, British Columbia--(Newsfile Corp. - March 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H0) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, today announced that BioGene Therapeutics Inc. (the "Company"), a company that it is a significant shareholder of, has appointed Raj S. Pruthi, MD, MHA, FACS, as a Director of the Company.
Vancouver, British Columbia--(Newsfile Corp. - February 25, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce that the Canadian Patent Office has allowed Canadian Patent Application No. 3127020, titled "A Cyclic Peptide", which relates to the Company's pain therapy program.
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce it has filed an International (PCT) patent application on February 5, 2026, having the application no. PCT/US2026/014110, and entitled "Delivery of CNS-active therapeutic agents".